Liang Cheng, President of International Society of Urological Pathology, Vice Chair for Translational Research at the Warren Alpert Medical School of Brown University, shared a post on LinkedIn:
“Congratulations to Drs. Emanuele Crupi, Daniele Raggi and colleagues on the publication of this timely article last month in Nature Reviews Urology.
HER2-directed antibody – drug conjugates (ADCs) are rapidly transforming the treatment landscape of urothelial carcinoma. Landmark clinical trials have established HER2-targeted therapy as a new therapeutic pillar. However, there is urgent need for urothelial carcinoma–specific HER2 testing and interpretation criteria. Current HER2 scoring systems are largely adapted from breast and gastroesophageal cancers, despite important differences in tumor biology, staining patterns, specimen types, and intratumoral heterogeneity. These limitations can substantially influence HER2 classification, patient selection, clinical trial eligibility, and ultimately access to life-extending therapies.
The authors provide a compelling framework highlighting the need for standardized HER2 assessment, consideration of spatial and temporal heterogeneity, and future integration of dynamic biomarkers such as liquid biopsy. As HER2 ADCs become increasingly central to precision medicine in bladder cancer, achieving diagnostic clarity will be essential to fully unlocking the potential of these breakthrough therapies.”
Title: HER2 in urothelial cancer: clinical speed outpacing diagnostic clarity
Authors: Emanuele Crupi, Filippo Pederzoli, Robert A. Huddart, Liang Cheng, Daniele Raggi
Other articles featuring Liang Cheng on OncoDaily.